Please try another search
For the three months ended 31 March 2022, Boditech Med Inc revenues increased 6% to W37.34B. Net income decreased 25% to W8.59B. Revenues reflect Other product segment increase from W1.81B to W3.74B, Immunity diagnosis equipment segment increase of 53% to W4.07B, China segment increase of 60% to W5.99B, South Korea segment increase from W1.2B to W3.34B. Net income was offset by R & D Expense increase of 35% to W4.16B (expense).
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 33096.23 | 34927.42 | 34862.8 | 34952.19 |
Gross Profit | 20054.82 | 21482.62 | 20790.16 | 20817.02 |
Operating Income | 5891.25 | 6519.66 | 8778.43 | 8105.22 |
Net Income | 6649.43 | 4879.79 | 9237.28 | 6278.57 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 231086.05 | 227901.66 | 217837.89 | 205666.7 |
Total Liabilities | 30787.65 | 30485.13 | 25066.84 | 21682.53 |
Total Equity | 200298.4 | 197416.53 | 192771.05 | 183984.17 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 3548.76 | 11767.91 | 9150.92 | 7330.95 |
Cash From Investing Activities | -11086.96 | -6375.71 | -18083.36 | 5969.63 |
Cash From Financing Activities | -2841.82 | 3770 | 666.63 | -6299.28 |
Net Change in Cash | -10262.85 | 8639.7 | -7930.12 | 6860.16 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review